ADAlison K. Death

Alison K. Death

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alison K. Death has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Valproate is an anti-androgen and anti-progestin

    by Alison K. Death, Kristine C.Y. McGrath, David J. Handelsman


  • Open Access

    Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?

    by Ted Wu, Kristine CY McGrath, Alison K Death

    Cardiovascular disease is a major complication of diabetes mellitus, especially for patients with diabetic nephropathy. The underlying factor or pathogenic mechanism that links diabetic nephropathy with cardiovascular disease is not known. The endothelial cell adhesion molecules, intercellular adhesion molecule-1 or vascular cell adhesion molecule-1, play a crucial role in the initiation of atherosclerosis. Levels of both cell adhesion molecules are raised by the diabetic and kidney disease states. This review focuses on these important cell adhesion molecules and their role in the pathogenesis of cardiovascular disease in diabetes and diabetic nephropathy.


  • Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis

    by Mark A. Sader, Kristine C. Y. McGrath, Michelle D. Hill, Ken F. Bradstock, Mark Jimenez, David J. Handelsman, David S. Celermajer, Alison K. Death

    Summary: Objective  There is evidence that male sex hormones influence the rate of progression of inflammatory and cardiovascular diseases. We have previously shown that human leucocytes and arterial cells isolated from male donors express more androgen receptor (AR) than those from female cells, with potentially pro‐atherogenic effects. We now investigate whether the gender difference in AR expression is due to genetic or hormonal regulation.Design and Patients  The influence of hormones on AR expression were studied in hpg mice (a mouse model of androgen deficiency) treated with testosterone, oestradiol or dihydrotestosterone (DHT). Blood samples were obtained for leucocyte AR expression and hormone levels from 53 subjects, grouped into: 12 male [six young adult (27–45 years), six elderly (71–79 years)] and six female (young adult 25–45 years) healthy controls; six male‐to‐female transsexuals (M2F; 20–50 years) receiving stable pharmacological oral oestrogen treatment; six female‐to‐male transsexuals (F2M; 31–51 years) receiving stable androgen replacement therapy; five younger men (18–56 years) who had been receiving long‐term androgen replacement therapy for hypogonadal disease; six elderly men (72–88 years) who had undergone medical castration for prostate cancer treatment; and 12 male bone marrow transplant recipients (BMT; 23–65 years) from either male or female donors.Measurements  Serum testosterone and oestradiol concentrations were measured by established immunoflurometric assays from unextracted human serum. AR mRNA levels were measured by RT–PCR and AR protein levels by western blot (cell culture) or immunohistochemistry (mouse arteries).Results  We found that AR mRNA levels were significantly down‐regulated in the leucocytes of hpg mice that were treated with exogenous testosterone, oestradiol or DHT. AR protein levels were also lower in aortic tissue from the same mice. In humans, we found AR expression was significantly down‐regulated by exogenous treatment with testosterone in F2M (31 ± 13%, compared with control) or oestradiol in M2F (22 ± 5%) but was significantly up‐regulated by endogenous testosterone in BMT (128 ± 17%). Low androgen levels measured in castrated older men were associated with markedly increased AR expression (207 ± 26%, P < 0·05) compared with age‐matched older male controls (100 ± 2%).Conclusions  Our results indicate a regulated ability of vascular cells to respond to sex hormones, with the effects of exogenous therapies differing markedly from those due to endogenous sex hormones. We conclude that the gender difference in AR expression in vascular cells is hormonally, rather than genetically, controlled.


  • TC-1 Is a Novel Tumorigenic and Natively Disordered Protein Associated with Thyroid Cancer

    by Margaret Sunde, Kristine C. Y. McGrath, Lei Young, Jacqueline M. Matthews, Elizabeth L. Chua, Joel P. Mackay, Alison K. Death

    A novel gene, thyroid cancer 1 (TC-1), was found recently to be overexpressed in thyroid cancer. TC-1 shows no homology to any of the known thyroid cancer-associated genes. We have produced stable transformants of normal thyroid cells that express the TC-1 gene, and these cells show increased proliferation rates and anchorage-independent growth in soft agar. Apoptosis rates also are decreased in the transformed cells. We also have expressed recombinant TC-1 protein and have undertaken a structural and functional characterization of the protein. The protein is monomeric and predominantly unstructured under conditions of physiologic salt and pH. This places it in the category of natively disordered proteins, a rapidly expanding group of proteins, many members of which play critical roles in cell regulation processes. We show that the protein can be phosphorylated by cyclic AMP-dependent protein kinase and protein kinase C, and the activity of both of these kinases is up-regulated when cells are stably transfected with TC-1. These results suggest that overexpression of TC-1 may be important in thyroid carcinogenesis.